Strs Ohio purchased a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 4,600 shares of the biotechnology company’s stock, valued at approximately $208,000.

Several other large investors have also bought and sold shares of the business. Principal Financial Group Inc. grew its stake in shares of Sarepta Therapeutics by 1.4% in the first quarter. Principal Financial Group Inc. now owns 9,455 shares of the biotechnology company’s stock worth $280,000 after acquiring an additional 129 shares in the last quarter. Ameritas Investment Partners Inc. grew its stake in shares of Sarepta Therapeutics by 6.3% in the second quarter. Ameritas Investment Partners Inc. now owns 4,561 shares of the biotechnology company’s stock worth $154,000 after acquiring an additional 271 shares in the last quarter. Advisor Group Inc. grew its stake in shares of Sarepta Therapeutics by 3.2% in the second quarter. Advisor Group Inc. now owns 10,402 shares of the biotechnology company’s stock worth $351,000 after acquiring an additional 326 shares in the last quarter. Legal & General Group Plc grew its stake in shares of Sarepta Therapeutics by 3.9% in the second quarter. Legal & General Group Plc now owns 17,590 shares of the biotechnology company’s stock worth $593,000 after acquiring an additional 663 shares in the last quarter. Finally, Parametric Portfolio Associates LLC grew its stake in shares of Sarepta Therapeutics by 0.8% in the second quarter. Parametric Portfolio Associates LLC now owns 109,852 shares of the biotechnology company’s stock worth $3,703,000 after acquiring an additional 818 shares in the last quarter. Institutional investors and hedge funds own 65.58% of the company’s stock.

Shares of Sarepta Therapeutics, Inc. (SRPT) opened at $54.16 on Friday. Sarepta Therapeutics, Inc. has a 1-year low of $26.26 and a 1-year high of $57.57. The company has a current ratio of 10.44, a quick ratio of 9.52 and a debt-to-equity ratio of 0.04.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its earnings results on Wednesday, October 25th. The biotechnology company reported ($0.20) EPS for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.66. Sarepta Therapeutics had a negative net margin of 112.08% and a negative return on equity of 51.72%. The business had revenue of $45.95 million during the quarter, compared to analysts’ expectations of $41.29 million. During the same period in the prior year, the company earned ($0.95) earnings per share. analysts expect that Sarepta Therapeutics, Inc. will post -3.11 EPS for the current fiscal year.

Several research firms have commented on SRPT. Robert W. Baird restated a “buy” rating and issued a $101.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, October 17th. Oppenheimer Holdings, Inc. restated a “buy” rating and issued a $76.00 price target on shares of Sarepta Therapeutics in a research note on Monday, October 16th. Goldman Sachs Group, Inc. (The) restated a “buy” rating and issued a $71.00 price target on shares of Sarepta Therapeutics in a research note on Friday, October 6th. ValuEngine downgraded shares of Sarepta Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, October 2nd. Finally, Royal Bank Of Canada restated a “buy” rating and issued a $64.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, October 3rd. One equities research analyst has rated the stock with a sell rating, six have assigned a hold rating and sixteen have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $63.59.

In other news, SVP Shamim Ruff sold 11,500 shares of the company’s stock in a transaction dated Tuesday, October 3rd. The shares were sold at an average price of $50.00, for a total value of $575,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 9.60% of the stock is currently owned by corporate insiders.

TRADEMARK VIOLATION NOTICE: “4,600 Shares in Sarepta Therapeutics, Inc. (SRPT) Acquired by Strs Ohio” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.watchlistnews.com/4600-shares-in-sarepta-therapeutics-inc-srpt-acquired-by-strs-ohio/1695225.html.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company. The Company focuses on the discovery and development of ribose nucleic acid (RNA)-targeted therapeutics for the treatment of rare neuromuscular diseases. It operates through discovering, developing, manufacturing and delivering therapies to patients with Duchenne muscular dystrophy (DMD).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.